Leuprolide acetate combined with gestrinone in treatment of uterine adenomyosis

Objective To investigate the efficacy of leuprolide acetate combined with gestrinone in the treatment of uterine adenomyosis. Methods A total of 84 patients with uterine adenomyosis treated at our hospital from January, 2014 to July, 2016 were enrolled and randomly divided into a control group and a combination group, 42 cases for each group. The control group were treated with leuprolide acetate and the combination group with leuprolide acetate and gestrinone. The VAS scores of dysmenorrhea, PBAC scores of menstrual amount, uterine volumes, and serum reproductive hormone levels of the two groups before treatment, at the end of the treatment, and 2 months after the treatment were observed and compared. Results The VAS score, the PBAC score, and the uterine volume of the combination group were significantly better than those of the control group (all P 0.05) . Conclusion Leuprolide acetate combined with gestrinone in the treatment of uterine adenocarcinoma is effective and safe, so it is worth being clinically generalized. Key words: Leuprolide acetate; Gestrinone; Uterine adenomyosis; Combined therapy